MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) is advancing an AI-driven voice analysis platform designed to detect drug and alcohol intoxication in real time, addressing growing demand for faster, scalable, and noninvasive impairment detection across workplace safety, healthcare, and public safety markets. By leveraging speech as a diagnostic biomarker, the company is pursuing a differentiated approach to multisubstance intoxication detection within an evolving AI healthcare landscape that includes HeartFlow Inc. (NASDAQ: HTFL), Recursion Pharmaceuticals Inc. (NASDAQ: RXRX), Tempus AI Inc. (NASDAQ: TEM), and Butterfly Network Inc. (NYSE: BFLY).
As substance-use patterns evolve and the limitations of traditional testing methods become increasingly apparent, AI-enabled diagnostics are gaining momentum as a potential next-generation solution for real-time decision-making and risk management. MindBio is targeting large commercial opportunities spanning workplace compliance, telehealth, and consumer health applications, positioning its voice-based platform within a broader transformation toward accessible, data-driven diagnostic technologies.
The company’s AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. MindBio is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction, and law enforcement.
For more information, see the full press release at https://ibn.fm/BZOb2. The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF.
